Journeys Metabolic’s Post

The expected market growth for GLP-1 drugs also creates a significant business opportunity for weight loss and digital health behavioral change solutions. What should digital health companies do now? Read latest article from Research2Guidance

💥 GLP-1 Market: The Once-in-a-Lifetime Business Opportunity for Digital Health Behavioral Change Solutions https://bit.ly/4bWyQCq The GLP-1 market is gearing up for unprecedented growth, heralding a golden era for digital health solutions targeting behavior change. With forecasts predicting multi-billion-dollar revenues, the landscape of chronic disease management, especially obesity, is on the brink of transformation. 📈 The Booming #Opportunity GLP-1 therapies offer a ray of hope for #obesity and #diabetes management, promising substantial weight loss benefits and enhanced glycemic control. But the sustainability of this growth faces hurdles, notably payer reluctance to cover lifelong medication costs. 💡 The #Payer Perspective  Payers (incl. insurers and healthcare systems) are cautious about funding lifelong drug regimens. Their reluctance is despite the predicted cost reductions due to the elimination of secondary diseases such as diabetes, knee problems, or psychological problems due to weight loss among millions of GLP 1 users. Payers are seeking cost-effective alternatives that address the root causes of these conditions and promote sustainable behavior change. 🧩 The Missing Piece: Digital #BehavioralChange While medical interventions play a role, behavior change is key to effective disease management. Digital health solutions fill this gap by offering personalized support, motivation, and guidance. 🌐 Capturing the Opportunity  The intersection of the booming GLP-1 market and the demand for behavior change solutions presents a unique opportunity for digital health companies. Leading providers have already stepped up, offering tailored programs for GLP-1 patients, e.g. ✔️ Vida Health expanded its services to include GLP-1 prescription and de-prescription, alongside coaching and behavior change support. ✔️ Omada Health launched a GLP-1 specific program aimed at chronic obesity, providing support for behavior and lifestyle changes. ✔️ DarioHealth initiated a GLP-1 behavior change program focused on achieving weight loss goals and fostering long-term behavior change. ✔️ Lark Health announced the GLP-1 Companion program, including side effect management and adherence support. ✔️ Noom Med was launched for clinical obesity, offering behavior change programs to reduce reliance on GLP-1 drugs. 🚀 Seizing the Opportunity Digital health solution providers must act swiftly to size the market and focus on three key areas: pre-prescription behavior change, bundled solutions during medication, and refresher programs post-prescription. With competition looming, 2024 is the deadline for readiness. To explore further : https://bit.ly/4bWyQCq #digitalhealth #GLP1 #globalhealth #healthcare #partnerships #marketopportunities #behaviourchangesolutions #medications #pharma

Variability in Huntington’s Disease Health Utilities: A Systematic Review and Policy Impact A recent study highlights the variability of health state utility estimates in Huntington's disease (HD), emphasizing the need for targeted research to refine quality of life assessments. The study conducted a systematic review of research from 2012 to 2022, evaluating 383 articles and identifying 16 articles with utility estimates from 11 studies. The review found that the EQ-5D was the most commonly used tool, and utility scores decreased with increasing severity of HD. The high variability in scores indicates uncertainty and the need for further research. The study concludes that more research is needed to understand patient preferences and valuation across all stages and symptoms of HD to improve healthcare strategies for HD patients. For more details please click the link! https://lnkd.in/gGwV-v5x #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

A new frontier has emerged in the world of healthcare benefits: Weight Loss Medications (WLMs). In 2023, WLMs took center stage as the top trend driver in the pharmacy space, with their impact only set to grow. While the monthly cost-per-patient may seem high, the potential for long-term health benefit savings is significant, as weight loss correlates with reduced comorbidities. With roughly 40% of US adults being labeled as obese, and 45% expressing interest in prescription medication for weight loss, the demand is real and the impact on pharmacy benefit plans is immediate. Our latest article explores ways employers can navigate weight loss medication within their pharmacy plan as they consider the wellbeing of their people.

Test-and-treat programs can help expand equitable access to lifesaving treatments. Krishna Udayakumar and I share highlights from a 10-country program in Devex: https://bit.ly/3xdvNXF Multi-sector partnerships like the COVID Treatment QuickStart Consortium can help navigate the complexity of introducing novel treatments. In partnership with Duke University, Americares, Clinton Health Access Initiative, Inc., and the COVID Collaborative, along with support from Pfizer and others, the Consortium brings together academic, regulatory, and public health experts to accelerate access to COVID-19 treatments for high-risk patients in LMICs. Learn more about the emerging lessons and what comes next. #GlobalHealh #HealthEquity #Partnerships #Sponsored

GLP-1 News Roundup: Stay Updated on the Latest in GLP-1 Research and Developments The field of GLP-1 research is advancing rapidly, with significant implications for diabetes and obesity treatment. Our latest news roundup provides a comprehensive overview of the most recent findings, innovations, and discussions in the GLP-1 landscape. In this article, we cover: - Breakthrough studies and clinical trials - New GLP-1 medications and therapies - Expert insights and analysis - Impact on patient care and treatment protocols Stay informed on the latest GLP-1 developments and their potential impact on healthcare. Read the full article here: https://lnkd.in/gkr28mrA #GLP1 #DiabetesResearch #HealthcareInnovation #TISinsurance #MedicalAdvancements #PatientCare #HealthcareNews

New weight-loss medications offer hope in addressing the #obesity crisis, but high costs create barriers to access. Expanding #Medicare coverage for these drugs could provide substantial health and financial benefits, according to a #USCSchaeffer Center white paper. Researchers estimate: - $175 billion in Medicare cost offsets in the first decade; - $700 billion in savings over 30 years; - 53% reduction in obesity prevalence among Medicare recipients after 10 years. These findings are particularly relevant for communities of color, who are disproportionately affected by obesity. https://lnkd.in/g6zHCNub USC Sol Price School of Public Policy   USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences

On #worldkidneyday, Chris Forbes CEO of Kidney Health Australia and Martin Haigh, Business Unit Director of BioPharmaceuticals at AstraZeneca explore the profound impact of #kidneydisease, with 1 in 6 hospital admissions attributed to chronic kidney disease and a substantial economic toll of $9.9 billion annually. "We know that to be successful in addressing kidney health, we need to work with the various comorbidities and treat the patient as a patient not as a disease," commented Chris. "There's a better opportunity for a more holistic approach to care," said Martin. "This focus on primary care and early detection is just so important. We can have an impact for the future so that we don't get a tsunami of patients on dialysis. The time to act is now." The Health Industry Hub interview explores this year's World Kidney Day theme 'Advancing equitable access to care and optimal medication practice' and the policy and advocacy initiatives that Kidney Health Australia is focusing on in the current year and in its pre-budget submission.   AstraZeneca's contributions to kidney #health #innovation and #research are highlighted. The interview also touches upon the desired changes in #healthcare delivery for kidney care, including the role of primary care programs and the expansion of #digitalhealth initiatives to reach diverse consumers. "The best outcome for patients is to not be on dialysis, because every day not on dialysis is a good day," Chris said.

Latest publication with Prof. Matan Cohen and Dr. Udi Kaliner- I think it is a powerful illustration of the situation that the medical system in Israel finds itself. Conclusion - Increased opioid use is independently associated with increased all-cause mortality among non-oncological patients. This result is most notable among young adults with little or no known comorbidities. These findings are consistent with results in other countries and seem more credible than previous Israeli reports. Healthcare regulators and providers should, therefore, act to curtail the increasing opioid prescriptions and devise and enhance controls in the healthcare system, which, until 2020, had very limited mechanisms in place. https://lnkd.in/d5WV3Ceb